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Introduction
Surgery plays a key role in the therapy of hepatobil-
iary and pancreatic cancer and 80-90% of patients
undergo surgery at least once. Although it is at present
the only modality with a chance for long-term survival,
curative surgery can be performed in only 40-50% of
patients referred to specialised surgical institutions.
Staging is an essential step in the management of pa-
tients with hepatobiliary and pancreatic tumours. Pre-
operative staging should ideally distinguish resectable
from unresectable disease and sort out candidates
that are best managed by palliative non-surgical treat-
ment. Intraoperative staging determines resectability
and the adequate surgical procedure for a specific pa-
tient and finally postoperative and histopathological
staging (pTNM) may indicate the appropriate adju-
vant therapy and should predict outcome.
Metastatic and locally invasive hepatobiliary and
pancreatic malignancy is, with a few exceptions, not
amenable to resection and less so to curative surgery.
Therefore the detection of tumour spread into distant
organs or locally into vessels is a crucial part of stag-
ing procedures to determine resectability. So far, this
issue was often answered during explorative laparo-
tomy but recent advances in radiological techniques
and diagnostic laparoscopy improved assessment of
tumour extension before laparotomy. This article dis-
cusses the problems in the preoperative staging and
detection of local invasion and metastases in hepato-
biliary and pancreatic cancer.
Preoperative staging
Percutaneous and endoscopic ultrasound
The majority (70-90%) of patients with pancreatic
or hepatobiliary carcinoma present with obstructive
jaundice and ultrasonography (US) is often used as
the first imaging modality. The accuracy of US can
exceed that of computed tomography (CT) and the
application of endoscopic ultrasound (EUS) promises
further improvement for small lesions that are anatom-
ically close to the stomach and the duodenum [1].
In experienced hands, well-defined structures can be
traced down to less than 10 mm [2]. US is an excel-
lent technique to determine the level and aetiology
of a bile duct obstruction and provides information
about the extension of an obstructive mass such as a
cholangiocarcinoma. In patients with hepatocellular
carcinoma (HCC) US is a reliable and routinely used
screening tool and often allows the detection of soli-
tary tumours without (Tl) and with invasion into the
hepatic or portal veins (T2, T3) and multifocal lesions
(T4). For surgical purposes we advocate an additive
use in conjunction with CT.
The main disadvantages of sonography are its
observer dependency and its limitations in obese pa-
tients. Moreover quality EUS is currently not avail-
able in all institutions. Many surgeons have also
difficulties creating virtual three dimensional images
of tumour extension and prefer CT and/or MRI.
Therefore, sonography is often used in screening
and for specific questions, such as the vicinity of a
tumour to portal veins in hilar cholangiocarcinoma.
Vascular involvement (T4) of hepatobiliary cancer
can be assessed by colour Doppler US with high
accuracy (91%) [3] and in combination with en-
dosonography (ES) [4] infiltration of duodenum and
peripancreatic tissue (T3) can be detected in pan-
creatic cancer. Lymph node size is not a reliable
indicator for the presence of metastasis and differen-
tiation between reactive and malignant lymph nodes
is notoriously difficult. Moreover the presence of
lymph node metastasis does not change treatment or
exclude a patient from potentially curative surgery
[5]. Small liver (<3-5 mm) and peritoneal metas-
tases may be missed by US in more than 15%.
Computed tomography scan (CT)
Progress of diagnostic imaging techniques especially
standardisation of the spiral abdominal CT clearly
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improved tumour staging of pancreatic and hepato-
biliary cancer and became the current gold standard
for preoperative staging [6]. Nevertheless, CT is of-
ten used in combination with other techniques. Its
accuracy to diagnose pancreatic cancer is more than
90% [7] because benign non-cystic pancreatic tu-
mours are rare. The distinction between malignancy
and an inflammatory mass of the pancreatic head in
a patient with chronic pancreatitis may be difficult
[8]. In a recent study, it allowed to predict tumour
resectability in 72% and its sensitivity and speci-
ficity for irresectability was 78 and 76%, respectively
[9,10]. Although its predictive value for vascular in-
filtration was 88% in a recent publication [10], the ra-
diological assessment of local tumour extension, e.g.
the degree of vascular encasement and institutional
resectability rates are variable [11-13]. Tumours in
the head of the pancreas can also originate within the
ampullary tissue (papilla, distal common bile duct,
duodenum) and these cancers represent different tu-
mour biologies with a more favourable outcome. The
prognostic value of CT in these patients is therefore
limited.
CT is capable to detect solitary, multifocal or dif-
fusely infiltrating HCC. Small HCC (less than 1-2
cm in diameter) can be difficult to diagnose using
dynamic intravenous-contrast enhanced CT with a
detection rate of only 50-58% [14]. More advanced
modalities such as CT during arteriography or CT
following injection of Lipiodol may increase the di-
agnostic accuracy for early HCC to 90-96% [14].
Portal vein invasion in large HCC is demonstrated
in up to 57% of cases using dynamic incremental
scanning [15] and invasion of hepatic veins is com-
mon (T2-T4). The indication for surgery, however,
is often not limited by the extension of HCC into
the hepatic vein, but rather by the presence of mul-
tifocal tumours, infiltration of the portal pedicle or
a reduced functional hepatic reserve in patients with
liver cirrhosis [16].
Endoscopic retrograde cholangiopancreatography
(ERCP)
Clinically jaundiced patients with hepatobiliary and
pancreatic malignancies often undergo ERCP that al-
lows definition of biliary pathology and alterations of
the main pancreatic duct and its side branches with
an accuracy of 95% [17]. ERCP is the gold standard
in the detection of subtle pancreatic and biliary ab-
normalities (Tis, Tl) but its value for tumour staging
is low [4]. The possibility to biopsy ductal pathol-
ogy, collect samples for cytological analysis and to
place stents or nasobiliary drains to relief obstructive
jaundice are often used in patients with hepatobiliary
and pancreatic malignancy. The physiologic changes
induced in a patient with obstructive jaundice have to
be included in the risk assessment. Although the use
of preoperative biliary drainage is a controversy, we
routinely use endoscopic stent placement in patients
with cancer of the pancreatic head or extrahepatic
bile duct tumours if bilirubin levels are > 100 n.mol/1
[18].
Magnetic resonance imaging and angiography
Magnetic Resonance Imaging (MR) including MR
cholangiopancreaticography and MR-angiography
[19] has the potential to replace CT in combina-
tion with diagnostic ERCP as the primary staging
examination. It allows in some patients the detec-
tion of tumours smaller than 1 cm in diameter [20].
However, since many hepatobiliary and pancreatic
tumours are not diagnosed in screening exams, the
sensitivity for small non-symptomatic tumours is
not its main advantage. The ability of MR to de-
fine tumour extension towards vascular structures
non-invasively makes MR attractive for preopera-
tive assessment. The reduction of cost and time of
examination compared with CT will facilitate its
routine application. MR-angiography also replaced
conventional angiography, a technique that was reg-
ularly used in many patients with hepatobiliary and
pancreatic cancer.
Diagnostic laparoscopy
Since all non-invasive staging examinations have
a false negative rate of 10-30% for small liver
and/or peritoneal metastases, diagnostic laparoscopy
has been advocated to avoid unnecessary laparotomy
and/or to prove the malignant nature of hepatobiliary
and pancreatic tumours by biopsy. Its routine use has
been advocated for patients with pancreatic cancer,
predominantly of the pancreatic body and tail. La-
paroscopy can improve tumour staging but its value
for the determination of resectability is questioned. In
pancreatic cancer detection of metastatic lesions by la-
paroscopy has been reported in 10% to 35% [21-23].
The value of concurrent peritoneal lavage cytology
and immunohistochemical examination that approx-
imately doubles the detection of minimal peritoneal
tumour spread has not been defined conclusively. We
use laparoscopy selectively in patients with locally
advanced non-metastatic cancer because in more than
75% of our pancreatic cancer patients laparoscopy did
not change course of treatment and allowed detection
of abdominal metastases in only 10%.
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Discussion
A balanced preoperative assessment of patients with
hepatobiliary and pancreatic tumours includes stag-
ing of the malignancy but also registration of oper-
ative risks, particularly pre-existing cardiopulmonary
disease to determine whether curative or palliative
treatment should be attempted. Potentially curative
surgery is defined by a radical resection (RO) of
the primary tumour and may include, lymphadenec-
tomy and in exceptional cases resection of mono- or
oligotopic metastases. Since morbidity and mortality
rates decreased to a minimum in many centres, more
radical resections to improve long-term survival can
be performed [24-26]. While this approach signifi-
cantly improved survival of patients with hepatobil-
iary cancer [27], further studies on radical surgery in
pancreatic cancer are planned and needed. Preopera-
tive staging of tumours includes primarily radiologic
techniques but analyses of functional reserve capac-
ity of the affected organ, particularly the liver [16],
molecular biological examinations of tumour-asso-
ciated antigens, monoclonal antibodies, cytokines,
genetic markers and the detection of minimal cancer
spread in blood, bone marrow and the peritoneal
cavity are currently under investigation and may in
the future improve staging.
New diagnostic tools have improved preoperative
staging and allow a more accurate definition of local
tumour extension and further technical developments
can be expected. When distant spread of cancer has
been excluded, surgical exploration is often indicated
since resectability is defined intraoperatively and re-
section is possible in many cancers of the liver,
bile duct and the pancreas. Therefore, the important
information for the surgeon collected by the above
mentioned studies, pertains to the presence of metas-
tases and definitive signs of irresectability, such as a
complex infiltration of vascular structures [28].
Advances in surgical technique such as the safe
resection and reanastomosis of portal structures, mul-
tivisceral resections, segmental liver resection with
preservation of functional hepatic capacity, have ex-
tended the spectrum of surgical indications towards
more advanced tumours. In addition to a considerable
reduction of both, morbidity and mortality [24] the
long-term survival of hepatobiliary cancer after rad-
ical surgery increased during recent years and even
for ductal adenocarcinoma of the pancreas 5-year
survival of 15-30% are reported.
We therefore conclude that although preoperative
staging certainly increased in accuracy, surgical ex-
ploration and resection are still essential in patients
with hepatobiliary and pancreatic malignancies. The
addition of biological markers and molecular stag-
ing may improve ability to treat these patients more
specifically and at an earlier stage, and new treatment
modalities may in the future allow to have effec-
tive treatment of advanced stages and local tumour
extension.
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